NYSE - Nasdaq Real Time Price USD

Novo Nordisk A/S (NVO)

122.75

-1.78

(-1.43%)

At close: April 18 at 4:00 PM EDT

123.54

+0.79

(+0.64%)

Pre-Market: 6:46 AM EDT

How The Weight-Loss Bonanza Prompted A ResMed Sell-Off — But Could Soon Drive Shares Higher

ResMed stock jumped Thursday after an analyst suggested the growing popularity of weight-loss drugs could drive use of its medical devices.

Investor's Business Daily 14 hours ago

RMD

LLY
-0.64%
NVO
-1.43%
India's Biocon developing its own version of Wegovy, clinical trial likely next year

Indian drugmaker Biocon, looking to grab a piece of the exploding weight-loss drug market as early as possible, is developing its own version of Novo Nordisk's wildly popular Wegovy and is prepared to conduct a clinical trial next year if needed, the CEO told Reuters. Wall Street has forecast the market for this new generation of obesity treatments reaching at least $100 billion by the end of the decade, and Biocon is taking steps to be a part of that windfall. "We're going to develop semaglutide for India even if it requires a clinical trial," Chief Executive Officer Siddharth Mittal said in an interview of the active ingredient in Wegovy and Ozempic.

Reuters 18 hours ago

BIOCON.NS

MITTAL.NS

NVO
-1.43%
Is Eli Lilly Stock A Buy After Weight-Loss Drug Succeeds In Sleep Apnea Patients?

Lilly is soon planning to ask global regulators to approve tirzepatide for sleep apnea treatment. Is Eli Lilly stock a buy?

Investor's Business Daily 18 hours ago

LLY
-0.64%
NVO
-1.43%
BIIB
-0.85%
Eli Lilly's (LLY) Tirzepatide Meets Goals in Sleep Apnea Studies

Data from Eli Lilly's (LLY) SURMOUNT-OSA studies show that treatment with tirzepatide results in a mean AHI reduction of up to 63% in adults with obstructive sleep apnea and obesity.

Zacks 21 hours ago

LLY
-0.64%
NVO
-1.43%
Metsera, a well-funded obesity drug startup, sees chance to challenge Lilly, Novo

It’s “early innings” in the obesity drug race, said Metsera CEO Clive Meanwell, whose company acquired a portfolio of medicines it aims to test in combination.

BioPharma Dive yesterday

LLY
-0.64%
NVO
-1.43%
Novo Nordisk (NVO) Stock Falls Amid Market Uptick: What Investors Need to Know

In the latest trading session, Novo Nordisk (NVO) closed at $123.46, marking a -0.36% move from the previous day.

Zacks 2 days ago

NVO
-1.43%
The Zacks Analyst Blog Highlights Microsoft, Novo Nordisk, United Parcel Service, Booking and Elevance Health

Microsoft, Novo Nordisk, United Parcel Service, Booking and Elevance Health are included in this Analyst Blog.

Zacks 3 days ago

NVO
-1.43%
MSFT

UPS
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons

Bagsværd, Denmark, 15 April 2024 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse. The company’s board members, executives and their associated persons have reported the transactions to Novo Nordisk and have given Novo Nordisk power of attorney on their behalf to publish trading in Novo Nordisk shares by t

GlobeNewswire 3 days ago

NONOF

NVO
-1.43%
Top Analyst Reports for Microsoft, Novo Nordisk & United Parcel

Today's Research Daily features new research reports on 16 major stocks, including Microsoft Corporation (MSFT), Novo Nordisk A/S (NVO) and United Parcel Service, Inc. (UPS).

Zacks 3 days ago

NVO
-1.43%
MSFT

UPS
Novo Nordisk and Ginkgo Bioworks Are Teaming Up. Here's Why That's Bullish for Both Stocks.

The collaboration could help solve challenges for both businesses.

Motley Fool 3 days ago

NVO
-1.43%
Novo Nordisk A/S - share repurchase programme

Bagsværd, Denmark, 15 April 2024 – On 6 February 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 20 billion to be executed during a 12-month period beginning 6 February 2024. Under the programme i

GlobeNewswire 3 days ago

NONOF

NVO
-1.43%
Beat the Market the Zacks Way: MediaAlpha, NVIDIA, Walmart in Focus

Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.

Zacks 3 days ago

^GSPC

MAX

WMT
Nvidia Leads 5 Stocks Near Buy Points As S&P 500 Tests Key Level

Nvidia, which bucked the S&P 500 downdraft last week, leads this weekend's watch list of five stocks near buy points.

Investor's Business Daily 5 days ago

NVDA

CCJ

^GSPC
Eli Lilly, Novo Euphoria Risks Disappointing Investors, Goldman Says

(Bloomberg) -- The weight loss drug frenzy that’s driven Eli Lilly & Co. and Novo Nordisk A/S to record peaks is raising the stakes for investors, according to Goldman Sachs Group Inc. analysts.Most Read from BloombergIsrael Versus Iran — What an Open War Between Them Could Look LikeTexas Warns of Possible Power Emergency Next WeekBiden Returns to White House as Israel Braces for Iran ResponseIsrael, Allies Mostly Block Unprecedented Attack From IranA $150 Billion Fortune Bolsters Qatari Royals

Bloomberg 6 days ago

LLY
-0.64%
NVO
-1.43%
European regulator concludes no suicide link to obesity drugs

The decision clears a concern hanging over GLP-1 medicines like Ozempic since reports of suicidal ideation and self-harm among people taking the drugs surfaced in July.

BioPharma Dive 6 days ago

NVO
-1.43%
LLY
-0.64%
7 A-Rated Aggressive Biotech Stocks to Bet On in 2024

The best biotech stocks to buy are in companies that put a lot of resources into research and development, often with nothing to show for it for years. Regulatory hurdles make finding biotech stocks to buy challenging if you don’t have the patience to wait it out. But when biotech companies win approval to sell and marketing a drug, the potential for profits can be off the charts. That’s why it’s a good idea to at least consider biotech, and whether they have a spot in your portfolio.InvestorPla

InvestorPlace 7 days ago

MRK

NVO
-1.43%
APM
Shed the Fat, Gain the Profits: 3 Weight-Loss Stocks to Own Until 2027

Weight-loss stocks remain the focus of many investors. The GLP-1 drugs that many companies have put forward address key health concerns like obesity and diabetes, which have become epidemics in many Western countries. The pandemic amplified These health-related issues, leading to sky-high demand for the companies’ weight-loss treatments. Now, some concerns around potential side effects and the ability to wean off of these drugs once a target weight has been hit are starting to ruminate in the ma

InvestorPlace 7 days ago

LLY
-0.64%
NVO
-1.43%
VKTX
All-Time High Flyers: 7 Stocks to Buy as the Market Peaks

If you’re wondering which stocks to buy in April, here’s a good place to start. The stock market is off to a difficult start in the second quarter. With the timing of interest rates getting pushed out further, the major averages have turned downwards. Since peaking on March 28, the benchmark S&P 500 index has declined nearly 2%. The dip has some on Wall Street wondering aloud if we’re at or close to the market’s peak and now entering what could be a steep selloff. Many analysts say a pullback is

InvestorPlace 7 days ago

MSFT

GE

JNJ
Novo Nordisk (NVO) Gains As Market Dips: What You Should Know

In the closing of the recent trading day, Novo Nordisk (NVO) stood at $124.93, denoting a +0.06% change from the preceding trading day.

Zacks 8 days ago

NVO
-1.43%
3 Obesity Drug Stocks Set to Skyrocket as Demand Goes Wild

The burgeoning interest in obesity drugs, particularly GLP-1 products such as Ozempic, Saxenda, and Mounjaro, marks a significant shift in the global approach to managing obesity. In this article, we look at three obesity drug stocks investors should consider. Shares of the companies producing these drugs soared in 2023 as demand outstripped supply and projections suggesting a market growth to $150 billion annually within the next decade. The surge is driven by the drugs’ effectiveness not only

InvestorPlace 8 days ago

LLY
-0.64%
NVO
-1.43%
DXCM

Performance Overview

Return	NVO	OMX Copenhagen 25 Index
YTD	+19.51%	+3.06%
1-Year	+46.34%	+1.59%
3-Year	+254.17%	+8.00%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Novo Nordisk A/S (NVO)

How The Weight-Loss Bonanza Prompted A ResMed Sell-Off — But Could Soon Drive Shares Higher

India's Biocon developing its own version of Wegovy, clinical trial likely next year

Is Eli Lilly Stock A Buy After Weight-Loss Drug Succeeds In Sleep Apnea Patients?

Eli Lilly's (LLY) Tirzepatide Meets Goals in Sleep Apnea Studies

Metsera, a well-funded obesity drug startup, sees chance to challenge Lilly, Novo

Novo Nordisk (NVO) Stock Falls Amid Market Uptick: What Investors Need to Know

The Zacks Analyst Blog Highlights Microsoft, Novo Nordisk, United Parcel Service, Booking and Elevance Health

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons

Top Analyst Reports for Microsoft, Novo Nordisk & United Parcel

Novo Nordisk and Ginkgo Bioworks Are Teaming Up. Here's Why That's Bullish for Both Stocks.

Novo Nordisk A/S - share repurchase programme

Beat the Market the Zacks Way: MediaAlpha, NVIDIA, Walmart in Focus

Nvidia Leads 5 Stocks Near Buy Points As S&P 500 Tests Key Level

Eli Lilly, Novo Euphoria Risks Disappointing Investors, Goldman Says

European regulator concludes no suicide link to obesity drugs

7 A-Rated Aggressive Biotech Stocks to Bet On in 2024

Shed the Fat, Gain the Profits: 3 Weight-Loss Stocks to Own Until 2027

All-Time High Flyers: 7 Stocks to Buy as the Market Peaks

Novo Nordisk (NVO) Gains As Market Dips: What You Should Know

3 Obesity Drug Stocks Set to Skyrocket as Demand Goes Wild

Performance Overview